Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.61 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.61 |
| ▸ | FAP | Q12884 | 2/20 | 0.61 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6238524 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL5647937 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL5647935 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9FAPDPP7 | |
| Hydrochloric Acid SCHEMBL3601691 | 0.99 | DPP4 (0.97) | DPP4DPP8DPP9FAPDPP7 | |
| Hydrochloric Acid SCHEMBL5652236 | 0.99 | DPP4 (0.97) | DPP4DPP8DPP9FAPDPP7 | |
| Hydrochloric Acid SCHEMBL5049190 | 0.99 | DPP4 (0.97) | DPP4DPP8DPP9FAPDPP7 | |
| Hydrochloric Acid SCHEMBL5652234 | 0.99 | DPP4 (0.97) | DPP4DPP8DPP9FAPDPP7 | |
| Trifluoroacetic Acid SCHEMBL5203128 | 0.92 | DPP4 (0.84) | DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL5203132 | 0.92 | DPP4 (0.84) | DPP4DPP8 | |
| Trifluoroacetic Acid SCHEMBL5696185 | 0.92 | DPP4 (0.84) | DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1658066-B9 | ADAMANTYLGLYCINE- BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | BRISTOL MYERS SQUIBB CO (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-1658066-B1 | ADAMANTYLGLYCINE- BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | BRISTOL MYERS SQUIBB CO (US) | 2009-09-30 | — | — | EP | disclosed |
| EP-1997489-A1 | Adamantylglycine derivatives as inhibitors of dipeptidyl peptidase IV for the treatment of diabetes | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1171121-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE PROMOTION OF GROWTH | FERRING BV (NL) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005012249-A2 | ADAMANTYGLYCINE- BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2003063903-A2 | MODULATION OF T LYMPHOCYTES USING DP IV INHIBITORS | PROBIODRUG AG (DE) | 2003-08-07 | — | — | WO | disclosed |
| US-6201132-B1 | INHIBITORS OF MEMBRANE-BOUND SERINE PROTEASE; AMINOACYL COMPOUNDS | FERRING B.V. (NL) | 2001-03-13 | — | — | US | disclosed |
| US-5939560-A | AMINE COMPOUNDS AS ENZYME INHIBITORS | FERRING B.V. (NL) | 1999-08-17 | — | — | US | disclosed |
| WO-1995015309-A1 | DP-IV-SERINE PROTEASE INHIBITORS | FERRING B.V. (NL) | 1995-06-08 | — | — | WO | disclosed |